C3i partners with Paladin Labs Inc. to offer Canadian clinicians a complimentary testing service to detect T315I mutation

MONTREAL, June 12, 2023 /PRNewswire/ - C3i Center Inc and Paladin Labs Inc., a subsidiary of Endo International plc (NASDAQ: ENDP), have partnered to launch a complimentary clinical testing program for the diagnosis of the T315I mutation in Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) patients in Canada.